MNTA Momenta Pharmaceuticals Inc.
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
- 13.83 P/E
- 12.87 P/S
- 2.81 P/B
- -2.193 EPS
- -146.29% Cash ROIC
- 11.20 Cash Ratio
- 0.00 / N/A % Dividend
- 598,553.00 Avg. Vol.
- 51.59M Shares
- 555.6M Market Cap.
Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th...
Barron's - Jan 26, 2015
Stocks Underperform for the Week: Momenta Pharmaceuticals Inc , Credit ... - Ashburn Daily
Insurance News Net - Jan 29, 2015
Motley Fool - Nov 5, 2014
Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q3 2014 Results ... - Seeking Alpha (registration)
TheStreet.com - Mar 4, 2014
Stafford Daily - Jan 6, 2015
Bar and Graph Report - 19 hours ago
Maxim Group Rating Disclosure on Momenta Pharmaceuticals, Inc. - Winston View
Stafford Daily - Jan 20, 2015
Schaeffers Research (blog) - Jan 23, 2015
Stafford Daily - Jan 13, 2015
GlobeNewswire (press release) - Jan 21, 2015
With local impact on both sides, Supreme Court sides with Teva in drug dispute - Philly.com (blog)